Cargando…
Umbilical cord blood: A promising source for allogeneic CAR-T cells
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability, exhaustion, and anergy. To overcome these limitations...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373021/ https://www.ncbi.nlm.nih.gov/pubmed/35965561 http://dx.doi.org/10.3389/fonc.2022.944248 |
_version_ | 1784767512385159168 |
---|---|
author | Liu, Dian-Dian Hong, Wei-Cong Qiu, Kun-Yin Li, Xin-Yu Liu, Yong Zhu, Li-Wen Lai, Wei-Xin Chen, Han- Yang, Hua-Qing Xu, Lu-Hong Fang, Jian-Pei |
author_facet | Liu, Dian-Dian Hong, Wei-Cong Qiu, Kun-Yin Li, Xin-Yu Liu, Yong Zhu, Li-Wen Lai, Wei-Xin Chen, Han- Yang, Hua-Qing Xu, Lu-Hong Fang, Jian-Pei |
author_sort | Liu, Dian-Dian |
collection | PubMed |
description | Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability, exhaustion, and anergy. To overcome these limitations, allogeneic CAR-T cells may be used as effective substitutes; however, which source would be the best substitute is unclear. In this study, we compared the immunophenotype and antitumor efficacy of anti-CD19 CAR-T cells derived from healthy donor cord blood (CB), healthy donor peripheral blood (PB), and PB of B-ALL patients [PB (patient)] in vitro and NOD-Prkdcem26cd52Il2rgem26Cd22/Nju (NCG)-immunodeficient mice, respectively. The results revealed that CAR-T cells derived from healthy donor CB and PB showed a higher proportion of naive T cells and longer tumor suppression in tumor-bearing mice than those of PB (patient). PB (patient) CAR-T cells had a higher proportion of regulatory T cells (Treg cells) and released high levels of interluekin-10 (IL-10), which also suggest a poor prognosis. Thus, CAR-T cells derived from healthy donors have better antitumor efficacy than CAR-T cells derived from PB (patient), and CB may be a good source of allogeneic CAR-T cells. |
format | Online Article Text |
id | pubmed-9373021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93730212022-08-13 Umbilical cord blood: A promising source for allogeneic CAR-T cells Liu, Dian-Dian Hong, Wei-Cong Qiu, Kun-Yin Li, Xin-Yu Liu, Yong Zhu, Li-Wen Lai, Wei-Xin Chen, Han- Yang, Hua-Qing Xu, Lu-Hong Fang, Jian-Pei Front Oncol Oncology Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability, exhaustion, and anergy. To overcome these limitations, allogeneic CAR-T cells may be used as effective substitutes; however, which source would be the best substitute is unclear. In this study, we compared the immunophenotype and antitumor efficacy of anti-CD19 CAR-T cells derived from healthy donor cord blood (CB), healthy donor peripheral blood (PB), and PB of B-ALL patients [PB (patient)] in vitro and NOD-Prkdcem26cd52Il2rgem26Cd22/Nju (NCG)-immunodeficient mice, respectively. The results revealed that CAR-T cells derived from healthy donor CB and PB showed a higher proportion of naive T cells and longer tumor suppression in tumor-bearing mice than those of PB (patient). PB (patient) CAR-T cells had a higher proportion of regulatory T cells (Treg cells) and released high levels of interluekin-10 (IL-10), which also suggest a poor prognosis. Thus, CAR-T cells derived from healthy donors have better antitumor efficacy than CAR-T cells derived from PB (patient), and CB may be a good source of allogeneic CAR-T cells. Frontiers Media S.A. 2022-07-29 /pmc/articles/PMC9373021/ /pubmed/35965561 http://dx.doi.org/10.3389/fonc.2022.944248 Text en Copyright © 2022 Liu, Hong, Qiu, Li, Liu, Zhu, Lai, Chen, Yang, Xu and Fang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Dian-Dian Hong, Wei-Cong Qiu, Kun-Yin Li, Xin-Yu Liu, Yong Zhu, Li-Wen Lai, Wei-Xin Chen, Han- Yang, Hua-Qing Xu, Lu-Hong Fang, Jian-Pei Umbilical cord blood: A promising source for allogeneic CAR-T cells |
title | Umbilical cord blood: A promising source for allogeneic CAR-T cells |
title_full | Umbilical cord blood: A promising source for allogeneic CAR-T cells |
title_fullStr | Umbilical cord blood: A promising source for allogeneic CAR-T cells |
title_full_unstemmed | Umbilical cord blood: A promising source for allogeneic CAR-T cells |
title_short | Umbilical cord blood: A promising source for allogeneic CAR-T cells |
title_sort | umbilical cord blood: a promising source for allogeneic car-t cells |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373021/ https://www.ncbi.nlm.nih.gov/pubmed/35965561 http://dx.doi.org/10.3389/fonc.2022.944248 |
work_keys_str_mv | AT liudiandian umbilicalcordbloodapromisingsourceforallogeneiccartcells AT hongweicong umbilicalcordbloodapromisingsourceforallogeneiccartcells AT qiukunyin umbilicalcordbloodapromisingsourceforallogeneiccartcells AT lixinyu umbilicalcordbloodapromisingsourceforallogeneiccartcells AT liuyong umbilicalcordbloodapromisingsourceforallogeneiccartcells AT zhuliwen umbilicalcordbloodapromisingsourceforallogeneiccartcells AT laiweixin umbilicalcordbloodapromisingsourceforallogeneiccartcells AT chenhan umbilicalcordbloodapromisingsourceforallogeneiccartcells AT yanghuaqing umbilicalcordbloodapromisingsourceforallogeneiccartcells AT xuluhong umbilicalcordbloodapromisingsourceforallogeneiccartcells AT fangjianpei umbilicalcordbloodapromisingsourceforallogeneiccartcells |